Close
What would you like to look for?

30 July 2021

RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (“Relief” or the “Company”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, has issued 1,000,000,000 additional registered shares out of the authorized share capital approved by the Annual General Meeting on 18 June 2021. The new shares were fully subscribed at par value by the Company’s wholly owned subsidiary, Relief Therapeutics International SA, and were listed on the SIX Swiss Exchange on 27 July 2021, based on a SIX listing prospectus approved by the Prospectus Office of SIX Exchange Regulation AG on 26 July 2021.
The new shares are being used in part for payments related to the recently announced AdVita and APR acquisitions, which are part of Relief’s transformation into a fully integrated diversified commercial-stage pharmaceutical company.

VISCHER acted as transaction counsel und listing agent. The team consists of Dr. Robert Bernet (Partner, Corporate/M&A), Dr. Peter Kühn (Counsel, Corporate/M&A) and Christian Schneiter (Senior Associate, Banking & Finance).

Categories: Banking & Finance, Deals & Cases

Authors